NewGenIvf Group (NASDAQ:NIVF) Major Shareholder Financial Lp Hrt Acquires 27,993 Shares

NewGenIvf Group Limited (NASDAQ:NIVF) major shareholder Financial Lp Hrt bought 27,993 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was bought at an average price of $0.92 per share, for a total transaction of $25,753.56. Following the completion of the acquisition, the insider directly owned 139,878 shares in the company, valued at approximately $128,687.76. The trade was a 25.02% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Friday, May 22nd, Financial Lp Hrt bought 137,541 shares of NewGenIvf Group stock. The stock was bought at an average price of $0.99 per share, for a total transaction of $136,165.59.

NewGenIvf Group Trading Up 9.6%

Shares of NASDAQ NIVF traded up $0.08 during mid-day trading on Wednesday, reaching $0.86. The company had a trading volume of 491,241 shares, compared to its average volume of 1,415,830. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.98 and a current ratio of 3.12. The company has a 50-day moving average price of $1.71 and a two-hundred day moving average price of $7.16. NewGenIvf Group Limited has a 1-year low of $0.72 and a 1-year high of $1,839.00.

NewGenIvf Group (NASDAQ:NIVF) last issued its earnings results on Tuesday, March 31st. The company reported ($287.24) earnings per share (EPS) for the quarter. The company had revenue of $1.42 million during the quarter. On average, research analysts expect that NewGenIvf Group Limited will post 4.74 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d)” rating on shares of NewGenIvf Group in a report on Monday, April 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, NewGenIvf Group presently has a consensus rating of “Sell”.

NewGenIvf Group Company Profile

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.